IDRSF Overview
Upcoming Projects (IDRSF)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IDRSF)
-
A Third View: Prescriber check in with sleep medicine specialist on their impression of Quviviq (daridorexant) in treating Insomnia
Ticker: IDRSF
Executed On: Oct 02, 2024 at 04:30 PM EDT -
A Second View: Prescriber check in with sleep medicine specialist on their impression of Quviviq (daridorexant) in treating Insomnia
Ticker: IDRSF
Executed On: Aug 02, 2024 at 04:00 PM EDT -
Prescriber check in with sleep medicine specialist on their impression of Quviviq (daridorexant) in treating Insomnia
Ticker: IDRSF
Executed On: Jul 31, 2024 at 11:00 AM EDT -
A Second View: Prescriber check in on Idorsia's insomnia drug Quiviviq
Tickers: IDRSF, IDIA.SXWX
Executed On: Aug 01, 2023 at 12:00 PM EDT -
Prescriber check in on Idorsia's insomnia drug Quiviviq
Tickers: IDRSF, IDIA.SXWX
Executed On: Jun 14, 2023 at 03:30 PM EDT -
A second look at the potential of aprocitentan (dual endothelin antagonist) for resistant hypertension in Idorsia's PRECISION study trial results
Tickers: IDRSF, IDIA.XSWX
Executed On: Nov 30, 2022 at 04:00 PM EST -
A look at the potential of aprocitentan (dual endothelin antagonist) for resistant hypertension in Idorsia's PRECISION study trial results
Tickers: IDRSF, IDIA.XSWX
Executed On: Nov 21, 2022 at 08:00 AM EST -
An international look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Sep 01, 2022 at 12:45 PM EDT -
A third look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 31, 2022 at 10:00 AM EDT -
A second look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 29, 2022 at 03:00 PM EDT -
A look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 25, 2022 at 05:15 PM EDT -
A third look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Ticker: IDRSF
Executed On: Jul 08, 2022 at 03:00 PM EDT -
A second look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Tickers: IDRSF, CINC, AZN, KBP Biosciences
Executed On: Jul 06, 2022 at 01:30 PM EDT -
A look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Ticker: IDRSF
Executed On: Jun 30, 2022 at 05:00 PM EDT
Upcoming & Overdue Catalysts (IDRSF)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (IDRSF)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
